Literature DB >> 22833826

Immunotherapy - Vaccines for allergic diseases.

Adrian Young-Yuen Wu1.   

Abstract

Allergic diseases are some of the most commonly encountered problems in clinical practice. Drugs such as corticosteroids and antihistamines can provide effective symptomatic relief, but do not alter the course of the disease. Specific immunotherapy (SIT) was first used to treat pollen allergy in 1911, and has since evolved into an effective treatment for allergic rhinitis and asthma. SIT has been shown in clinical studies to reduce symptoms and medication use in patients with allergic rhinitis and asthma. Recent studies also showed that the therapeutic benefit is long-lasting after the completion of three to five years of treatment. SIT can also effectively reduce the risk of developing asthma and new allergic sensitizations in children with allergic rhinitis.

Entities:  

Keywords:  Allergic rhinitis; allergen; asthma; desensitization; hayfever; prevention

Year:  2012        PMID: 22833826      PMCID: PMC3378232          DOI: 10.3978/j.issn.2072-1439.2011.07.03

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  25 in total

1.  Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials.

Authors:  M J Abramson; R M Puy; J M Weiner
Journal:  Am J Respir Crit Care Med       Date:  1995-04       Impact factor: 21.405

2.  A double-blind study of the discontinuation of ragweed immunotherapy.

Authors:  R M Naclerio; D Proud; B Moylan; S Balcer; L Freidhoff; A Kagey-Sobotka; L M Lichtenstein; P S Creticos; R G Hamilton; P S Norman
Journal:  J Allergy Clin Immunol       Date:  1997-09       Impact factor: 10.793

3.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

Authors:  Christian Möller; Sten Dreborg; Hosne A Ferdousi; Susanne Halken; Arne Høst; Lars Jacobsen; Antti Koivikko; Dieter Y Koller; Bodo Niggemann; Lene A Norberg; Radvan Urbanek; Erkka Valovirta; Ulrich Wahn
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

4.  Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial.

Authors:  V A Varney; J Edwards; K Tabbah; H Brewster; G Mavroleon; A J Frew
Journal:  Clin Exp Allergy       Date:  1997-08       Impact factor: 5.018

5.  Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study.

Authors:  G B Pajno; G Barberio; F De Luca; L Morabito; S Parmiani
Journal:  Clin Exp Allergy       Date:  2001-09       Impact factor: 5.018

6.  Long-term clinical efficacy of grass-pollen immunotherapy.

Authors:  S R Durham; S M Walker; E M Varga; M R Jacobson; F O'Brien; W Noble; S J Till; Q A Hamid; K T Nouri-Aria
Journal:  N Engl J Med       Date:  1999-08-12       Impact factor: 91.245

7.  Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study.

Authors:  L Nielsen; C R Johnsen; H Mosbech; L K Poulsen; H J Malling
Journal:  J Allergy Clin Immunol       Date:  1996-06       Impact factor: 10.793

8.  A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects.

Authors:  L Haugaard; R Dahl; L Jacobsen
Journal:  J Allergy Clin Immunol       Date:  1993-03       Impact factor: 10.793

9.  Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study.

Authors:  S M Walker; V A Varney; M Gaga; M R Jacobson; S R Durham
Journal:  Allergy       Date:  1995-05       Impact factor: 13.146

10.  Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy.

Authors:  G Hedlin; H Heilborn; G Lilja; K Norrlind; K O Pegelow; C Schou; H Løwenstein
Journal:  J Allergy Clin Immunol       Date:  1995-12       Impact factor: 10.793

View more
  7 in total

Review 1.  Immunotherapy in allergy and cellular tests: state of art.

Authors:  Salvatore Chirumbolo
Journal:  Hum Vaccin Immunother       Date:  2014-05-02       Impact factor: 3.452

2.  Food allergy and related risk factors in 2540 preschool children: an epidemiological survey in Guangdong Province, southern China.

Authors:  Guang-Qiao Zeng; Jia-Ying Luo; Hui-Min Huang; Pei-Yan Zheng; Wen-Ting Luo; Ni-Li Wei; Bao-Qing Sun
Journal:  World J Pediatr       Date:  2015-08-08       Impact factor: 2.764

3.  Co-sensitization to silkworm moth (Bombyx mori) and 9 inhalant allergens among allergic patients in Guangzhou, Southern China.

Authors:  Baoqing Sun; Peiyan Zheng; Nili Wei; Huimin Huang; Guangqiao Zeng
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

4.  Sensitization to silk allergen among workers of silk filatures in India: a comparative study.

Authors:  Giriyanna Gowda; Anwith Huluvadi Shivalingaiah; Anagha Manakari Vijayeendra; Nivedita Sarkar; Chitra Nagaraj; Nugehally Raju Ramesh Masthi
Journal:  Asia Pac Allergy       Date:  2016-04-28

Review 5.  Rhinitis.

Authors:  Sheryl Beard
Journal:  Prim Care       Date:  2013-11-28       Impact factor: 2.907

Review 6.  DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy.

Authors:  Qingjia Chi; Zichang Yang; Kang Xu; Chunli Wang; Huaping Liang
Journal:  Front Pharmacol       Date:  2020-01-28       Impact factor: 5.810

Review 7.  Human immunology and immunotherapy: main achievements and challenges.

Authors:  Jezabel Varadé; Susana Magadán; África González-Fernández
Journal:  Cell Mol Immunol       Date:  2020-09-02       Impact factor: 22.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.